Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Trends Endocrinol Metab. 2014 Nov;25(11):576-85. doi: 10.1016/j.tem.2014.08.001. Epub 2014 Aug 30.
Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in Western countries, ranging from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular cancer. Although the mechanisms underlying disease progression are incompletely understood, lipotoxic events in the liver resulting in inflammation and fibrosis appear to be central. Free fatty acids and their metabolites are potentially lipotoxic mediators triggering liver injury, suggesting a central role for metabolic lipases. These enzymes are major players in lipid partitioning between tissues and within cells, and provide ligands for nuclear receptors (NRs). We discuss the potential role of intracellular lipases and their lipolytic products in NAFLD. Because tissue-specific modulation of lipases is currently impossible, targeting NRs with ligands may open novel therapeutic perspectives.
非酒精性脂肪性肝病 (NAFLD) 是西方国家最常见的慢性肝病,其病变范围从单纯性脂肪变性到脂肪性肝炎、肝硬化和肝细胞癌。尽管疾病进展的机制尚不完全清楚,但肝脏中导致炎症和纤维化的脂毒性事件似乎是关键。游离脂肪酸及其代谢产物可能是触发肝损伤的脂毒性介质,提示代谢脂肪酶起着核心作用。这些酶是组织间和细胞内脂质分配的主要参与者,并为核受体 (NRs) 提供配体。我们讨论了细胞内脂肪酶及其脂肪分解产物在 NAFLD 中的潜在作用。由于目前无法对脂肪酶进行组织特异性调节,因此用配体靶向 NR 可能会开辟新的治疗前景。